Trial reportJournal of neurology, neurosurgery, and psychiatry2006
Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
Trial report in Journal of neurology, neurosurgery, and psychiatry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.
- Traditional Chinese exercise for quality of life, cognition, sleep in Parkinson's disease: a systematic review and meta-analysis.Frontiers in psychology · 2026Pooled it
- Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.Journal of Alzheimer's disease : JAD · 2023Trial
- RETRACTED: Effects of L-DOPA Monotherapy on Psychomotor Speed and [Biological psychiatry · 2019Trial
- Trial
- A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.Science translational medicine · 2026Article
- Distinct and combined interferon-ɑ/β-receptor-1 loss in neurons and astrocytes disrupt brain energy metabolism and drive Parkinsonian dementia.Journal of biomedical science · 2026Article
- Molecular Pathogenesis of Memory Impairment in Parkinson's Disease: An Exploration of Underlying Mechanisms.Health science reports · 2026Article
- Misfolded Proteins and Cognitive Decline: Mechanistic Insights into Neurodegenerative Disorders.Neurology international · 2026Review
- Cognitive Fluctuation Scale in Non-demented Patients with Parkinson's Disease.Movement disorders clinical practice · 2025Article
- On Levodopa Interactions with Brain Disease Amyloidogenic Proteins at the Nanoscale.ACS omega · 2025Article
- Senolytic and senomorphic secondary metabolites as therapeutic agents inFrontiers in neurology · 2023Review
- Semantic fluency deficits and associated brain activity in Parkinson's disease with mild cognitive impairment.Brain imaging and behavior · 2022Article
- Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.Translational neurodegeneration · 2022Review
- Cognitive workload during verbal abstract reasoning in Parkinson's disease: a pilot study.The International journal of neuroscience · 2021Article
- Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials.Neurology and therapy · 2020Article
- Professor Keith Andrew Wesnes (1950 to 2020).Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.Singapore medical journal · 2019Article
- Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2019Article
- Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease.Journal of speech, language, and hearing research : JSLHR · 2018Article
- Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease.Neurobiology of aging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLevodopa (L-dopa) is the gold standard treatment for Parkinson's disease, but a lack of clear efficacy combined with a perceived liability to neuropsychiatric side effects has limited L-dopa use in patients with parkinsonism and dementia. Therefore, the effect of L-dopa on the cognitive profile of dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) is unclear.
aimTo ascertain the acute and long-term effects of L-dopa on aspects of attention and cognition in patients with DLB and PDD, and to compare these with the effects in Parkinson's disease.
methodBaseline cognitive and motor function was assessed off L-dopa in patients with Parkinson's disease (n = 22), PDD (n = 27) and DLB (n = 11) using standard "bedside" measures and a computerised programme detecting reaction times and accuracy. All patients then underwent an acute L-dopa challenge with subsequent subjective and objective analysis of alertness, verbal recall, reaction times and accuracy. The same parameters were measured after 3 months on L-dopa to assess the prolonged effect.
resultsAcute L-dopa challenge considerably improved motor function and subjective alertness in all patients without compromising either reaction times or accuracy, but increased fluctuations were noted in both groups with dementia. Neuropsychiatric scores improved in patients with Parkinson's disease both with and without dementia on L-dopa at 3 months. Although patients with Parkinson's disease also had better mean global cognitive function at this time, mean verbal attention and memory deteriorated, and patients with PDD had slower reaction times in some tests. No patient had a marked deterioration over this time. Patients with DLB did not experience any adverse cognitive or neuropsychiatric effects after 3 months of L-dopa treatment.
conclusionThe use of L-dopa in patients with parkinsonism with dementia does not adversely affect cognitive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.